Liver, biliary and pancreas

Plasma leucine enkephalin is increased in liver disease

J R THORNTON AND M S LOSOWSKY

From the Department of Medicine, St James's University Hospital, Leeds

SUMMARY Plasma methionine enkephalin is increased in liver disease and may contribute to some of the clinical manifestations of hepatic failure. To determine if another 'small' opioid peptide is increased in the plasma of patients with liver disease, leucine enkephalin was measured by radioimmunoassay. Its plasma concentration was raised approximately five-fold in patients with acute liver disease (median 1490 pmol/l, range 830–2420) and three-fold in patients with cirrhosis with ascites (960 pmol/l, 470–2900), compared with disease controls (325 pmol/l, 180–740) and healthy controls (305 pmol/l, 180–560). The increase in plasma leucine enkephalin was proportional to the degree of liver damage, as judged in the patients with acute liver disease by its correlation with the prothrombin time \( r=0.691, \ p<0.01 \) and alanine aminotransferase \( r=0.502, \ p<0.05 \), and in the patients with cirrhosis by its negative correlation with the plasma albumin \( r=−0.743, \ p<0.001 \). It is unclear whether the raised plasma leucine enkephalin in liver disease is a consequence of diminished hepatic inactivation, increased secretion from sympathetic nerves and adrenal glands, or both.

The liver may play a major role in the elimination of blood borne opioid peptides of octapeptide size or less.1 In favour of this hypothesis, the pentapeptide methionine enkephalin1,2 but not the much larger opioid peptide, \( \beta \)-endorphin,3 is increased in liver disease. Raised plasma levels of some opioid peptides may contribute to some of the clinical manifestations of hepatic failure. This possibility is indicated by the recent finding that administration of an opioid antagonist, naloxone, to patients with primary biliary cirrhosis produced an opioid withdrawal reaction, alleviated their pruritus and fatigue, and reduced their plasma bilirubin.4

Five other opioid peptides comprising eight or fewer amino acids are known (methionine enkephalin-arg-phe, methionine enkephalin-arg-gly-leu, leucine enkephalin, adrenorphin and dynorphin 1–8). If the hypothesis of predominant hepatic elimination of these peptides is correct, they may be found to be raised in the plasma of patients with liver disease. Therefore, we have investigated whether this is the case for one such peptide, leucine enkephalin (tyr-gly-gly-phe-leu).

Methods

SUBJECTS

Six groups, each comprising 15 subjects, were studied: (i) Acute liver disease: 12 caused by paracetamol overdose and three by hepatitis A. Seven of these patients had hepatic encephalopathy but none had a markedly raised plasma creatinine at the time of blood sampling (Table). Three patients in this group subsequently died of liver failure. (ii) Cirrhosis with ascites: the presence of ascites was confirmed by abdominal ultrasound and diagnostic aspiration of ascitic fluid. As assessed by Pugh's modification of Child's classification,4 eight of these patients were grade B and seven were grade C. (iii) Cirrhosis without ascites: by Pugh's classification, nine of these patients were grade A and six grade B. The absence of ascites was confirmed by abdominal ultrasound.

In both groups (ii) and (iii), the presence of cirrhosis was confirmed by liver biopsy. The predominant aetiologies were alcohol and primary biliary cirrhosis. (iv) Severe chronic renal failure: of the 15, eight were receiving haemodialysis and four peritoneal dialysis. In these 12 patients samples were collected before dialysis. (v) Disease controls: all were hospital inpatients. Three patients had congestive cardiac failure, three had acute exacerbations
Plasma leucine enkephalin is increased in liver disease

Table  Plasma albumin, creatinine, alanine aminotransferase (ALT) and prothrombin time ratio (PTR) expressed as medians with ranges in the six groups of subjects

<table>
<thead>
<tr>
<th>Group</th>
<th>Group</th>
<th>Group</th>
<th>Group</th>
<th>Group</th>
<th>Group</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin (g/l)</td>
<td>41 (38-46)</td>
<td>29 (18-36)</td>
<td>39 (33-44)</td>
<td>37 (32-43)</td>
<td>37 (31-45)</td>
<td>42 (39-48)</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>106 (78-140)</td>
<td>92 (78-117)</td>
<td>78 (47-102)</td>
<td>1045 (895-1120)</td>
<td>82 (52-98)</td>
<td>68 (51-79)</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>8936 (6194-19165)</td>
<td>82 (48-168)</td>
<td>50 (31-98)</td>
<td>36 (21-33)</td>
<td>26 (24-47)</td>
<td>23 (19-29)</td>
</tr>
<tr>
<td>PTR</td>
<td>4 (2-7-7-3)</td>
<td>1-6 (1-2-2-5)</td>
<td>1-3 (1-0-1-5)</td>
<td>1-2 (1-0-1-4)</td>
<td>1-2 (1-0-1-3)</td>
<td>1-0 (1-0-1-2)</td>
</tr>
</tbody>
</table>

of asthma, three bacterial pneumonia, three acute or chronic pancreatitis, two untreated coeliac disease and one chronic intestinal pseudo-obstruction. (vi) Fifteen healthy controls.

None of the subjects had had a recent gastrointestinal bleed. There were no significant differences in age between groups (ii)-(vi). Median ages in years with range in these groups were: group (ii) 60, 37–71; group (iii) 57, 35–74; group (iv) 54, 32–66; group (v) 56, 36–70; group (vi) 60, 30–77. The patients with acute liver disease (group i) were significantly younger (median 22 years, range 18–30, p<0.001) than the other groups. There were no significant differences in sex distribution between any of the groups.

Venous, non-fasting, blood samples were collected from the resting subjects into chilled citric acid containing bottles.2 Leucine enkephalin was measured by radioimmunoassay, using antibody, tracer and reagents purchased from Immuno Nuclear Corporation, Stillwater, Minnesota, USA. The assay procedure and its validation, including high performance liquid chromatography, were identical to that previously described for methionine enkephalin.3 Within and between assay coefficients of variation were 6% and 8%. Recovery rate was 79%. Minimum sensitivity was 180 pmol/l. Non-specific binding ranged from 3-6–4-7%. Cross-reactivity of the antibody was: dynorphin 1–8 6%, gly-gly-phe-leu 4%, methionine enkephalin 2%, methionine enkephalin-arg-phe, methionine enkephalin-arg-gly-leu, dynorphin 1–17, peptide E, peptide F and β-endorphin all <0-01%.

Data are expressed as medians with ranges. To convert leucine enkephalin values to pg/ml, multiply by 0-556. The statistical significance of differences was determined by the Mann-Whitney U test.

Results

Plasma leucine enkephalin was considerably raised in all the patients with acute liver disease (median 1490 pmol/l, range 830–2420) and in the majority of those with cirrhosis and ascites (960, 470–2900) compared with those with cirrhosis without ascites (415, 180–620), the disease controls (325, 180–740) and the healthy controls (305, 180–560) (Figure). The peptide’s level was slightly increased in the patients with renal failure (560, 180–1020) versus the two groups of controls.

In the acute liver disease patients, plasma leucine enkephalin correlated with the prothrombin time (r=0.691, p<0.01) and the alanine aminotransferase (r=0.502, p<0.05) measured in aliquots of the same blood sample. In the patients with cirrhosis (groups ii and iii combined) the peptide’s level was negatively correlated with plasma albumin (r=−0.743, p<0.001) but not with the bilirubin, alanine aminotransferase or alkaline phosphatase. It did not correlate significantly with the plasma creatinine in any of the groups with hepatic or renal failure.

Biochemical data regarding the six groups of subjects are shown in the Table.

Discussion

This study shows that leucine enkephalin is considerably increased in the plasma of patients with cirrhosis, with ascites, and in patients with acute liver disease. The increase is roughly proportional to the degree of liver damage, as judged in the patients with acute liver disease, by the correlation of the peptide’s concentration with the alanine aminotransferase and prothrombin time and in the patients with cirrhosis, by the correlation with the plasma albumin. These findings cannot be explained as a non-specific response to illness, as the disease control subjects, some of whom were very ill, had normal plasma levels of the peptide. It seems unlikely that the raised plasma leucine enkephalin in the patients with liver disease is a consequence of leakage from damaged hepatocytes because these cells are a poor source of enkephalins. Furthermore, we found considerably increased plasma levels of the peptide in some of the patients with cirrhosis, many of whom had only
modest hepatic inflammation as judged by their alanine aminotransferase.

The origins of plasma leucine enkephalin are unclear. Possible sources are the gut, adrenal glands and sympathetic nerves.

The data do not permit a conclusion as to whether the increased plasma leucine enkephalin is a consequence of diminished hepatic inactivation, increased secretion, or both. Leucine enkephalin is degraded rapidly by a variety of enzymes, and the liver contains a high concentration of at least one of these enzymes, leucine aminopeptidase. In dogs, the portal venous content of leucine enkephalin was approximately twice that in the hepatic vein. The suggestion that the liver enzymatically degrades opioid peptides of octapeptide size or less, such as pentapeptide leucine enkephalin, is consistent with its inactivation of gastrin and cholecystokinin peptides of various chain lengths. Thus, gastrin peptides comprising eight or fewer amino acids and those cholecystokinin peptides with seven or less amino acids were cleared rapidly by the liver, whereas their larger counterparts were much more resistant. Adrenal and sympathetic activity are usually raised in severe liver disease, with the exception that, in acute liver disease, sympathetic tone may be normal. Therefore, enhanced secretion from the adrenal glands and/or sympathetic nerves may be contributing to the peptide's raised plasma level. The slightly raised level of plasma leucine enkephalin in the patients with chronic renal failure also suggests the possibility that urinary excretion and/or degradation by renal peptidases may play a minor role in the peptide's elimination.

Compared with a previous similar study, the present data indicate that leucine enkephalin is approximately six times more plentiful in normal plasma than methionine enkephalin. Both enkephalins are predominantly delta receptor agonists. Leucine enkephalin's actions include reduction of arterial pressure. Therefore, its raised plasma level in hepatic impairment may contribute to the haemodynamic disturbances of liver disease. If sufficiently sustained, as occurs in the patients with cirrhosis, we suggest that it and other vasodilator opioid peptides such as methionine enkephalin, may promote the development of portal hypertension and ascites by stimulating increased sympathetic nervous tone.

These data were presented to the Autumn meeting of the British Society of Gastroenterology, 1988. We thank the Mason Medical Research Foundation for financial support, Mrs S Shires for technical assistance and Drs A Davison and E Will for allowing us to study the patients with renal failure.

References

1 Thornton JR, Losowsky MS. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 1989; 8: 53–9.
Plasma leucine enkephalin is increased in liver disease

14 Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 1975; 88: 295–308.
Plasma leucine enkephalin is increased in liver disease.

J R Thornton and M S Losowsky

Gut 1989 30: 1392-1395
doi: 10.1136/gut.30.10.1392

Updated information and services can be found at:
http://gut.bmj.com/content/30/10/1392

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Gastrointestinal hormones (848)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/